Mazdutide: dual GLP-1 and glucagon receptor agonist promotes weight loss in adults with obesity and overweight
A phase 2 study demonstrates the efficacy and safety of mazdutide, a once-weekly GLP-1 and glucagon receptor agonist, across multiple dose ranges.
Medical Affairs
3 min read
November 7, 2025
Mazdutide (LY3305677) is a dual GLP-1 and glucagon receptor agonist administered once weekly, developed to enhance body weight reduction with a favorable tolerability profile. During ObesityWeek 2025, results from a phase 2 study (NCT06124807) evaluating the efficacy and safety of mazdutide in adults with obesity or overweight without type 2 diabetes were presented.
This randomized, double-blind, placebo-controlled trial included 179 participants who received placebo or mazdutide at doses of 6 mg, 10 mg, or 16 mg, administered subcutaneously once weekly for 48 weeks. The primary endpoint was the percent change in body weight from baseline to week 32, while secondary endpoints included weight reduction through week 48, proportion of participants achieving ≥5% and ≥10% weight loss, changes in BMI, and safety outcomes.
The full results — including the magnitude of weight loss and detailed safety profile — will be presented at the official session, but preliminary findings indicate that mazdutide produces significant, dose-dependent weight loss with good tolerability and a safety profile comparable to other incretin-based therapies.
These findings highlight the potential of mazdutide as a new once-weekly therapeutic option for obesity management, combining the incretin effect of GLP-1 with moderate glucagon receptor activation, which contributes to increased energy expenditure and preservation of lean mass.
Editorial note: This content was developed with the support of artificial intelligence technologies to optimize writing and information structure. All material was carefully reviewed, validated, and complemented by human experts prior to publication, ensuring scientific accuracy and adherence to editorial best practices.
References:
- Hsia SH, Weideman AMK, Araujo O, Coskun T, Haupt A, Mather KJ. Mazdutide (LY3305677) in participants with obesity or overweight: a phase 2 dose-finding study. Presented at: ObesityWeek 2025, Abstract Oral-104.
